ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Biology
Medicine / Sub specialtie
Public health
Pure sciences
Research
Education
Social Sciences
Medicine / Pharmacology
Communication
Chemistry
all records (70)

Languages
English
Spanish
Portuguese
German

Countries
Brazil
USA
Indonesia
Spain
Ukraine
Italy
Cuba
Argentina
Colombia
Chile
all records (67)

Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
all records (24)

Filter  
 
5.137  Articles
1 of 515 pages  |  10  records  |  more records»
Angiotensin converting enzyme inhibitors (ACE-Is), angiotensin receptor blockers (ARBs) and mineralocorticoid receptor antagonists (MRAs) reduce morbidity, mortality and hospitalisations from hypertension, chronic kidney disease and heart failure. Patient... see more

The role and adverse effects of mineralocorticoid receptor overactivation in the pathophysiology of heart failure (HF) is well-recognised. MR antagonists (MRAs) have been tested in HF and shown to be effective in improving outcomes. Steroid-type MRAs spir... see more

Recent clinical studies continued to show beneficial outcome of mineralocorticoid receptor (MR) antagonists for treating heart failure. However, the side effects of these drugs, particularly in the kidney, justified more studies to explore the cell type-s... see more

A comparative assessment of the effect of mineralocorticoid receptor antagonists on changes in galectin 3 and matrix metalloproteinase 1 fibrosis markers has been carried out on 106 examinations (average age (69 + 10.37) years) with type 2 DM and CCF of i... see more

Tarczykowska Agata, Kochanski Bartosz, Wolowiec Lukasz, Surowiec Agnieszka, Plaskiewicz Anna, Zukow Walery. Ocena skutecznosci i bezpieczenstwa farmakoterapii inhibitorami aldosteronu w niewydolnosci serca = Evaluation of the efficacy and safety of pharma... see more

Mineralocorticoid Receptor (MR) is a classic steroid hormone receptor. Its traditional role is to mediate aldosterone to control electrolyte homeostasis and blood pressure via renin-angiotensin system. Besides aldosterone, MR can also bind to glucocortico... see more

Arginine vasopressin (a peptide neuroendocrine hormone) levels are elevated in patients with HF. Acting through 3 receptor subtypes, it can cause vasoconstriction and cardiac remodelling (receptors V1a), adrenocorticotropic hormone release (receptors V1b)... see more

The mineralocorticoid receptor (MR) was first identified as a blood pressure regulator, modulating renal sodium handling in response to its principal ligand aldosterone. The mineralocorticoid receptor is also expressed in many tissues other than the kidne... see more

The neurohormonal model of HF has provided the rationale for the use of drug classes blocking the effectors of both the RAAS and SNS at different sites, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), minera... see more

1 of 515 pages  |  10  records  |  more records»